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The treatment of intracranial 
hypertension depends on the type of 
intracranial hypertension and on the 
developmental stage of the illness. The 
treatment is first of all an etiologic one in 
order to remove the cause that has caused 
the intracranial pressure increase; 
simultaneously, there is an attempt to stop 
the pathogenic mechanisms that impact on 
the nervous structures, and a symptomatic 
treatment is applied in order to reduce the 
intensity of the clinical syndrome. 
The term of etiologic treatment refers to 
the etiology of the intracranial 
hypertension, that is to the immediate cause 
that generates the intracranial pressure 
increase: for instance, in the case of a 
cerebral metastasis leading to ICH, the 
name of etiologic treatment is given to the 
action of metastasis extirpation, and it has 
no connection to the etiology and the 
therapy of the original neoplasia (1, 2, 3, 4, 
15).  
The intracranial hypertension treatment 
can be complex by combining three 
therapeutic methods used concomitantly or 
successively, or only the pathogenic therapy 
and the symptomatic one are used, 
depending on the clinical stage and the 
paraclinical explorations.  
The type of intracranial hypertension 
establishes the treatment that must be 
applied:  
1. the treatment is etiologic in:  
- expansive intracranial processes: 
cerebral tumors, intracranial hematomas, 
cerebral abscesses, hydatid cyst, etc., in the 
case of parenchymatous intracranial 
hypertension,  
- hypertensive encephalopathy in the 
case of vascular intracranial hypertension,  
- thrombosis of intracranial vessels, 
venous or arterial, in the case of vascular 
intracranial hypertension,  
- CSF circulation disorders due to the 
existence of a ventricular or paraventricular 
tumor with the occurrence of an 
obstructive hydrocephalus,  
- CSF resorption disorders in acute 
meningitis.  
2. the pathogenic treatment is applied in:  
- the ICH cases with known etiology, 
which are mentioned above, in order to 
stop the development of the pathogenic 
mechanisms that have already started,  
- the parenchymatous intracranial 
hypertension due to posttraumatic brain 
edema, hypoxic brain edema caused by 
secondary posttraumatic cerebral ischemia 
or in the case of sub-arachnoid 
hemorrhage, general intoxications with 
neurotoxins (endogenous or exogenous), 
etc.  
- the vascular intracranial hypertension 
due to cerebral venous thrombosis, 
thrombosis of superior sagittal sinus with a 
decrease in the venous drainage and the 
blockage of the CSF absorption, or in the 
case of the secondary ischemic brain edema 
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in the ischemic stroke caused by the 
occlusion or the stenosis of the great 
cerebral vessels,  
- intracranial hypertension due to CSF 
dynamic disorder  
- idiopathic intracranial hypertension 
especially in order to block the 
development of certain complications 
depending on possible pathogenic 
mechanisms.  
3. symptomatic treatment:  
- all the cases of intracranial 
hypertension, when the etiologic and/or 
pathogenic therapy is applied, benefit from 
the symptomatic treatment, depending on 
the presented symptomatology,  
- in idiopathic intracranial hypertension. 
(1, 2, 15, 27, 28) 
 Based on the manifested clinical 
syndrome, there may be several situations 
that correspond to the evolutionary stages 
of intracranial hypertension:  
- the patient is conscious and the 
cerebral exploration reveals a lesion that 
may cause the development of an 
intracranial hypertension syndrome – the 
treatment is etiologic and it addresses the 
lesion that may cause ICH,  
- the patient is conscious with incipient 
ICH signs, therefore with a compensated 
ICH syndrome, with or without focal 
neurological signs – the treatment is 
etiologic, pathogenic and symptomatic,  
- the patient is in a critical condition, 
with consciousness disorders, with a 
decompensating ICH syndrome or in a 
coma due to the decompensation of the 
intracranial hypertension – the treatment is 
etiologic, pathogenic and symptomatic, and 
it is applied immediately.  
Therapeutic recommendations  
Etiologic treatment  
I. If there is an expansive intracranial 
process that caused the intracranial 
hypertension syndrome, the etiologic 
treatment consists in the surgical 
intervention for the lesion removal.  
In numerous situations, the 
neurosurgical techniques allow the ablation 
of that particular expansive intracranial 
process:  
- the extirpation of the cerebral tumors is 
complete or partial, depending on the 
tumor location relative to the eloquent 
nervous structures, and depending on the 
benign or malign character of the 
neoformation. The removal of the 
neoformation makes the supplementary 
endocranial volume disappears as a first 
moment in the development of the 
intracranial hypertension, as well as 
removing the compressive effect on the 
CSF circulation paths and the edematous 
effect on the adjacent nervous parenchyma. 
(Figure 1) 
- the expansive traumatic lesions, with or 
without a traumatic brain edema, are 
surgically solved by the evacuation of the 
traumatic hematomas, the removal of the 
edematous cerebral dilaceration, etc., 
(Figure 2) 
- other expansive intracranial lesions, 
non-tumor or non-traumatic lesions, such 
as the cerebral abscess, the dural empyema, 
the hydatid cyst, etc., are surgically solved, 
usually by a complete evacuation. (4, 6, 8)  
II. In the case of hypertensive 
encephalopathy, the etiologic treatment is 
the treatment of the hypertensive crises 
with a gradual, but fast enough, return, to 
normal values of the blood pressure, 
concomitantly to the brain edema decrease 
and the clinical improvement of the ICH 
syndrome.  
III. In the case of the vascular 
intracranial hypertension, due to cerebral 
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venous thrombosis, thrombosis of superior 
sagittal sinus, etc., anti-thrombotic and anti-
coagulant substances may be used.  
IV. In the ischemic stroke caused by the 
occlusion or stenosis of the great vessels, 
substances with fibrinolytic action may be 
used: intravenous thrombolysis, fibrinogen 
degrading enzymes, etc. The thrombotic 
occlusion of the Sylvian artery can benefit 
from an extra-intracranial anastomosis with 
the superficial temporal artery. The carotid 
endarteroctomy and the angioplasty, with 
the mechanic removal of the sanguine 
coagulum or with the installation of an 
arterial stent, have been used in emergency 
cases, but certain procedures are presented 
especially as prophylactic surgical 
treatments for the cerebral stroke in 
patients with repeated transitory ischemic 
cerebral vascular accidents.  
V. The intracranial hypertension, due to 
CSF resorption disorders, secondary to an 
acute meningitis benefits from the etiologic 
treatment of the bacterial meningitis, which 
decreases the meningeal inflammation and 
reduces the changes in CSF resorption.  
VI. In intracranial hypertension of acute 
liver failure with endotoxic etiology, the 
etiologic treatment consists of performing a 
hepatic transplant. The decision on the 
performance of the hepatic transplant is 
made based on the neurological prognosis 
monitoring the intracranial pressure in the 
fulminating case of a hepatic failure of a 
degree ≥ 3, (West Haven Criteria of 
Altered Mental Status In Hepatic 
Encephalopathy).  
VII. In the intracranial hypertension of 
the posterior reversible encephalopathy 
syndrome (PRES) with a non-hypertensive 
etiology, due to the neurotoxic action of 
certain immuno-suppressors or cytostatics, 
the treatment is etiologic, and it consists of 
interrupting the causing medication, with 
the progressive improvement within a few 
days. 
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Figure 1. Olfactory groove meningioma: MRI 
preoperative (A) with secondary intracranial 
hypertension and postoperative (B) image with 
normal cerebral ventricles 
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Figure 2. CT image of right subdural hematoma and 
secondary intracranial hypertension 
 
Pathogenic treatment  
 The pathogenic treatment is used in all 
types of intracranial hypertension in order 
to stop the pathogenic mechanisms by 
means of which various causes bring about 
the intracranial pressure increase, and 
which cause the compensating capacities of 
the endocranial pressure increases to be 
exceeded. (3, 4, 9, 19, 20, 22)  
 The purpose of the pathogenic 
treatment is:  
- to act on the development of the brain 
edema, and once this has occurred, it must 
be reduced by medication therapies or there 
must be an attempt to decrease the effect of 
the neoformation or of the perilesional 
brain edema on the rest of the nervous 
parenchyma by surgical decompression,  
- to prevent the occurrence of internal 
hydrocephalus and, in the case of an already 
existing obstructive hydrocephalus, to 
decrease the volume of the ventricular CSF,  
- to prevent endocranial circulatory 
disorders or to bring back to normal values 
the already affected cerebral sanguine 
circulation, in order to stop the 
development of the cerebral ischemia,  
- in the case of certain signs that 
announce a complication, to stop the 
development of that particular process 
(decompression of the optic nerve in 
idiopathic ICH in order to stop the 
evolution of cecity, etc.),  
- before the occurrence, or at the first 
signs of intracranial hypertension 
decompensation through the appearance of 
a cerebral hernia, to try various maneuvers 
for the protection of the nervous 
parenchyma by using methods such as 
ventricular drainage, sub-temporal 
decompressive craniectomy, craniectomy of 
posterior cerebral fosse with the excision of 
the posterior arch of the atlas, etc. ( 9, 23, 
26, 30, 31) 
Symptomatic treatment  
The symptomatic treatment is necessary 
in most cases of intracranial hypertension in 
order to decrease the intensity of the 
symptoms until the etiopathogenic therapy 
comes into effect, and then concomitantly 
with it. Antalgics, antiemetics, antivertigos, 
anticonvulsants, antithermics, sedatives, 
etc., are used, depending on the existing 
symptomatology. (1, 2, 21)  
Therapeutic schemes in intracranial 
hypertension  
Treatment of the brain edema  
 The pathogenic treatment of the brain 
edema depends on the type of edema:  
- the cellular cerebral (cytotoxic) edema 
occurs due to the intra/extracellular osmotic 
pressure disequilibrium, with an intact 
brain-blood barrier, and it is reduced by 
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diuretics;  
- the hydrostatic extracellular brain 
edema in hypertensive encephalopathy is 
caused by the increase in the hydrostatic 
pressure from the cerebral capillaries 
secondary to a severe AHT, and it is 
produced by an ultra-filtration mechanism 
with an intact brain-blood barrier;  
- the oncotic (vasogenic) extracellular 
brain edema represents a severe alteration 
of the brain blood barrier (open brain-
blood barrier), it has a peri-tumor 
development or in other lesions by through 
a vasogenic mechanism, and it responds 
favourably to corticosteroids;  
- the mixed brain edema, cellular and 
extracellular, is the most frequent type of 
brain edema; the typical features occur 
from the start in the case of the traumatic 
brain edema.  
 Diuretics and corticosteroids are used in 
order to decrease the brain edema.(2, 5, 7, 
8, 10)  
The mannitol is an osmotic diuretic, and 
it is used in a dose of 0.25 – 1 g / Kgc 
intravenously; the effect occurs after 10 – 
15 minutes, it lasts for approximately two 
hours and it may be repeated after 6 hours. 
It is efficient in the case of the brain edema 
with intact brain-blood barrier. The 
administration of larger doses does not 
reduce the intracranial pressure further, but 
there is a longer period of action. The 
mannitol must be carefully administered in 
order not to increase a hematoma by 
decreasing the volume of the parenchyma 
with an edema around. During the 
mannitol therapy, one must verify the 
serous osmolarity, which must be 
maintained between 300 – 315 mOsm / 
L.The osmolarity can be calculated, and 
must be maintained below 320 mOsm/ L.  
 The classical belief is that mannitol can 
be administered in sufficiently large doses, 
taking into account the serous osmolarity, 
in order to prevent a possible secondary 
renal insufficiency. Recent studies have 
specified the fact that the renal 
insufficiency, which can occur after the 
mannitol administration, is related more to 
the preexisting high blood pressureor to the 
existence of a diabetes mellitus, than to 
osmolarity or to the mannitol doses. (2, 12, 
20, 25, 29) 
 Furosemide is an ansa diuretic, it is used 
in a dose of 10 – 40 mg, which is 
administered intravenously or as an initial 
dose of 0.5 – 1 mg / Kgc; it also decreases 
the CSF production.  
 The combination of these two diuretics 
is more efficient and it requires the 
monitoring of the sanguine electrolytes 
(potassium).  
 Corticosteroids (dexamethasone) are 
efficient in the vasogenic brain edema as 
they repair the brain-blood barrier. A 
quantity of 4 – 20 mg of dexamethasone is 
administered intravenously, and the effects 
are felt in a few hours. (12, 16, 18, 29) 
Decrease in CSF secretion and excess  
 The acetazolamide and corticosteroids 
reduce the production of cerebrospinal 
fluid, and they are used in order to reduce 
the CSF volume. Acetazolamide is a 
sulfonamide that specifically inhibits the 
carbonic anhydrase at the level of the renal 
tube, ciliary body, choroid plexus, and in 
the digestive mucous membrane. The 
acetazolamide administration in doses of 
250 – 1000 mg / day gradually reduces the 
CSF production; it is necessary to monitor 
the electrolytes and the sanguine pH. (3, 5, 
7, 11, 28, 31)  
A reduced CSF secretion also happens 
after the administration of mannitol and 
furosemide.  
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 The rapid removal of the CSF excess 
can be performed by means of a ventricular 
drainage during the intracranial pressure 
monitoring, which ensures the intracranial 
pressure control, or by means of an external 
ventricular drainage in emergency cases. 
The CSF drainage by lumbar puncture or 
by lumbar catheter is not used due to the 
risk of cerebral herniation. In the case of an 
idiopathic intracranial hypertension 
syndrome, the lumbar-peritoneal shunt is 
sometimes used, while, in the case of an 
obstructive hydrocephalus, ventricular-
peritoneal shunting systems may be used. 
(3, 6) 
Maintaining a normal cerebral sanguine 
perfusion  
 The sanguine arterial pressure increase 
is recommended in order to maintain an 
appropriate cerebral perfusion pressure 
when the monitoring reveals a significant 
increase in the intracranial pressure. The 
hypertensive therapy for the systemic blood 
pressure increase includes the 
administration of colloidal solutions, 
intravenous vasopressors, such as dopamine 
or phenylephrine. (1, 8, 10, 15, 26) 
 In the case of the intracranial 
hypertension syndrome in traumatic brain 
injury, the systemic arterial pressure may 
usually increase up to 150 – 170 mm Hg. In 
the case of decreased values of the cerebral 
perfusion pressure, sanguine pressure 
increasing measures can be applied even 
with the risk of an ICP increase as the 
purpose is to maintain the normal values of 
the cerebral perfusion pressure. (3, 5, 6, 9, 
10) 
 In the case of non-traumatic intracranial 
hypertension syndrome and in the absence 
of the cerebral hemorrhage, the blood 
pressure can increase up to 180 mm Hg. 
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